Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a critical liver disease that can progress to more severe manifestations, such as cirrhosis, yet no effective targeted therapies are available. Here, we identify that ATF4, a master transcription factor in ER stress response, promotes liver fibrosis by facilitating a stress response-independent epigenetic program in hepatic stellate cells (HSCs). Unlike its canonical role in regulating UPR genes during ER stress, ATF4 activates epithelial-mesenchymal transition (EMT) gene transcription under fibrogenic conditions. HSC-specific depletion of ATF4 suppresses liver fibrosis in vivo. Mechanistically, TGFβ resets ATF4 to orchestrate a unique enhancer program for the transcriptional activation of pro-fibrotic EMT genes. Analysis of human data confirms a strong correlation between HSC ATF4 expression and liver fibrosis progression. Importantly, a small molecule inhibitor targeting ATF4 translation effectively mitigates liver fibrosis. Together, our findings identify a mechanism promoting liver fibrosis and reveal new opportunities for treating this otherwise non-targetable disease. Liver fibrosis is a disease that lacks effective treatments. This study reveals that ATF4 drives fibrosis by activating hepatic stellate cells and that pharmacological inhibition of ATF4 reduces liver fibrosis, offering an opportunity for new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Excessive accumulation of extracellular matrix (ECM) is a hallmark of liver fibrosis (1).”
From Matrix mechanical remodeled carrier-free nanosystem for programmable closed-loop reversal of liver fibrosis via STING alkylation (2025) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672 · cited 1×
“Since we have ATF4-knockdown cells in our experiments (as a negative control), we were able to precisely recognize the ATF4 band on the western blots.”
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 2×
“We appreciate your comments that could potentially broaden the scope of our study, and we would like to address them from the following aspects.”
Control of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+
Bootman, M. D., Missiaen, L., Parys, J. B., De Smedt, H., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143 · cited 2×
“Together, we hope you can concur that the anti-fibrotic effects of ISRIB are primarily through targeting HSCs.”
La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastriti, M. E., Lönnerberg, P., Furlan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0414-6 · Cited by 4,118
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
THE MAMMALIAN UNFOLDED PROTEIN RESPONSE
Schröder, M., & Kaufman, R. J. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.074134 · Cited by 3,026 · cited 2×
“The claim of ATF4-specific deletion in HSCs should be substantiated with additional evidence, possibly by single-cell RNA sequencing analysis, FACS sorting of HSCs and non-HSCs populations, or other confirmatory techniques.”
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Cited by
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 58
Li, L., Zhu, Z., Jiang, X., Tang, Y. J., Li, J., Zhang, Z., Ding, B., Li, X., Yu, M., & Gan, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114059 · Cited by 26
Si, L., Zhou, Q., Zhao, R., Xie, L., Cao, W., & Feng, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217613 · Cited by 15
Self-citationKong, Y., Chen, Z., Nie, Z., & Chen, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107823 · Cited by 18
Interactions between hepatic stellate cells and immune cells: Implications for liver fibrosis
Xie, D., Huang, Y., Yu, Y., Jin, W., Zhang, X., & Yu, F. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168062 · Cited by 13
Metadata
- Authors
- Yang, L.-X., Qi, C., Lu, S., Ye, X.-S., Merikhian, P., Zhang, D.-Y., Yao, T., Zhao, J.-S., Wu, Y., Jia, Y., Shan, B., Chen, J., Mou, X., You, J., Li, W., & Feng, Y.-X.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Sir Run Run Shaw Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- The University of Texas MD Anderson Cancer Center (US)
- Zhejiang Chinese Medical University (CN)
- Zhejiang Provincial People's Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Westlake University (CN)
- Corresponding author
- You, Jia
- Li, Wenbo
- ORCID
- Venue
- Nature Communications
- Published
- 2025-01-09
- Volume
- 16
- Issue
- 1
- Pages
- 524-524
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11718104
- OpenAlex
- W4406221865
- Cited by
- 57
- References
- 78
- Citations by year
- 2026: 39 · 2025: 18
- FWCI
- 32.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (32300642, 82188102, 32270783, 32100949)
- Ministry of Science and Technology of the People's Republic of China (2020YFA0803300)
- Zhejiang University
- Peking University
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- liver fibrosis, ATF4, hepatic stellate cells, epithelial-mesenchymal transition, enhancer program, TGF-beta, endoplasmic reticulum stress response, epigenetic regulation, small molecule inhibitors
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Male, Mice, Inbred C57BL, Transforming Growth Factor beta, Epigenesis, Genetic, Mice, Activating Transcription Factor 4, Hepatic Stellate Cells, Epithelial-Mesenchymal Transition, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells. https://app.cochat.ai/papers/10.1038/s41467-024-55738-1
- The paper
- Yang, L.-X., Qi, C., Lu, S., Ye, X.-S., Merikhian, P., Zhang, D.-Y., Yao, T., Zhao, J.-S., Wu, Y., Jia, Y., Shan, B., Chen, J., Mou, X., You, J., Li, W., & Feng, Y.-X. (2025). Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells. Nature Communications. https://doi.org/10.1038/s41467-024-55738-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.